Cooper Companies Files 2024 10-K
Ticker: COO · Form: 10-K · Filed: Dec 6, 2024 · CIK: 711404
Sentiment: neutral
Topics: 10-K, annual-report, ophthalmic-goods
TL;DR
COOPER's 2024 10-K is in. Full financial picture for the year ending Oct 31.
AI Summary
The Cooper Companies, Inc. filed its 10-K for the fiscal year ending October 31, 2024. The company, headquartered in San Ramon, CA, operates in the Ophthalmic Goods sector. Key financial details and operational highlights are presented in this annual report.
Why It Matters
This filing provides a comprehensive overview of Cooper Companies' financial performance and strategic positioning for the fiscal year 2024, crucial for investors and stakeholders to assess the company's health and future prospects.
Risk Assessment
Risk Level: medium — The filing contains standard disclosures for a public company, but the complexity of financial reporting and the specific industry risks associated with ophthalmic goods necessitate a medium risk assessment.
Key Numbers
- FY 2024 — Fiscal Year (Reporting period for the 10-K filing)
Key Players & Entities
- COOPER COMPANIES, INC. (company) — Filer of the 10-K
- 20241031 (date) — Fiscal year end date
- 20241206 (date) — Filing date
- San Ramon, CA (location) — Company headquarters and mailing address
- 3851 (industry_code) — Standard Industrial Classification for Ophthalmic Goods
FAQ
What is the primary business of The Cooper Companies, Inc.?
The Cooper Companies, Inc. is primarily involved in the Ophthalmic Goods sector, as indicated by its SIC code 3851.
When did The Cooper Companies, Inc. file its 10-K report?
The 10-K report was filed on December 6, 2024.
What fiscal year does this 10-K filing cover?
This 10-K filing covers the fiscal year ending October 31, 2024.
Where is The Cooper Companies, Inc. headquartered?
The Cooper Companies, Inc. is headquartered in San Ramon, CA.
What is the SEC file number for this filing?
The SEC file number for this 10-K filing is 001-08597.
Filing Stats: 4,233 words · 17 min read · ~14 pages · Grade level 15.7 · Accepted 2024-12-06 16:21:48
Key Financial Figures
- $0.10 — ange on which registered Common Stock, $0.10 par value COO Nasdaq Global Select Mar
Filing Documents
- coo-20241031.htm (10-K) — 2025KB
- coo-ex1012_20241031x10k.htm (EX-10.12) — 19KB
- coo-ex21_20241031x10k.htm (EX-21) — 78KB
- coo-ex23_20241031x10k.htm (EX-23) — 2KB
- coo-ex311_20241031x10k.htm (EX-31.1) — 9KB
- coo-ex312_20241031x10k.htm (EX-31.2) — 9KB
- coo-ex321_20241031x10k.htm (EX-32.1) — 5KB
- coo-ex322_20241031x10k.htm (EX-32.2) — 5KB
- coo-20241031_g1.jpg (GRAPHIC) — 25KB
- coo-20241031_g2.jpg (GRAPHIC) — 69KB
- coo-20241031_g3.jpg (GRAPHIC) — 37KB
- coo-20241031_g4.jpg (GRAPHIC) — 28KB
- coo-20241031_g5.jpg (GRAPHIC) — 28KB
- coo-20241031_g6.jpg (GRAPHIC) — 28KB
- coo-20241031_g7.jpg (GRAPHIC) — 28KB
- 0000711404-24-000074.txt ( ) — 12027KB
- coo-20241031.xsd (EX-101.SCH) — 63KB
- coo-20241031_cal.xml (EX-101.CAL) — 115KB
- coo-20241031_def.xml (EX-101.DEF) — 302KB
- coo-20241031_lab.xml (EX-101.LAB) — 946KB
- coo-20241031_pre.xml (EX-101.PRE) — 652KB
- coo-20241031_htm.xml (XML) — 1849KB
Risk Factors 19
Item 1A. Risk Factors 19
Unresolved Staff Comments 39
Item 1B. Unresolved Staff Comments 39 Item 1C. Cybersecurity 39
Properties 41
Item 2. Properties 41
Legal Proceedings 42
Item 3. Legal Proceedings 42
Mine Safety Disclosures 42
Item 4. Mine Safety Disclosures 42 PART II
Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 43
Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 43
Management's Discussion and Analysis of Financial Condition and Results of Operations 45
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 45
Quantitative and Qualitative Disclosure about Market Risk 54
Item 7A. Quantitative and Qualitative Disclosure about Market Risk 54
Financial Statements and Supplementary Data 55
Item 8. Financial Statements and Supplementary Data 55
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 88
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 88
Controls and Procedures 88
Item 9A. Controls and Procedures 88
Other Information 92
Item 9B. Other Information 92
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 92
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 92 PART III
Directors, Executive Officers and Corporate Governance 93
Item 10. Directors, Executive Officers and Corporate Governance 93
Executive Compensation 93
Item 11. Executive Compensation 93
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 93
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 93
Certain Relationships and Related Transactions, and Director Independence 93
Item 13. Certain Relationships and Related Transactions, and Director Independence 93
Principal Accounting Fees and Services 93
Item 14. Principal Accounting Fees and Services 93 PART IV
Exhibits and Financial Statement Schedules 94
Item 15. Exhibits and Financial Statement Schedules 94
Form 10-K Summary 98
Item 16. Form 10-K Summary 98 3 THE COOPER COMPANIES, INC. AND SUBSIDIARIES PART I
Forward-Looking Statements
Forward-Looking Statements This Annual Report on Form 10-K contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These include statements relating to plans, prospects, goals, strategies, future actions, events or performance and other statements which are other than statements of historical fact, including: statements regarding the expected impact of global macroeconomic conditions, and statements regarding acquisitions (including the acquired companies' financial position, market position, product development and business strategy, expected cost synergies, expected timing and benefits of the transaction, difficulties in integrating entities or operations, as well as estimates of our and the acquired entities' future expenses, sales and earnings per share) that are forward-looking. In addition, all statements regarding anticipated growth in our net sales, anticipated effects of any product recalls, anticipated market conditions, planned product launches, restructuring or business transition expectations, regulatory plans, and expected results of operations and integration of any acquisition are forward-looking. To identify these statements, look for words like "believes," "outlook," "probable," "expects," "may," "will," "should," "could," "seeks," "intends," "plans," "estimates" or "anticipates" and similar words or phrases. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Among the factors that could cause our actual results and future actions to differ materially from those described in forward-looking statements are those described in our Securities and Exchange Commission filings, including the "Business," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of
. Business
Item 1 . Business . OVERVIEW The Cooper Companies, Inc. (Cooper, we or the Company), is a global medical device company with a mission to improve lives one person at a time. We partner with health care providers worldwide to improve patient outcomes and deliver practice-building resources and training. By listening closely to the healthcare providers and patients, we fulfill the needs of today while focusing on the opportunities of tomorrow through innovation and strategic investment. Cooper operates through two business segments, CooperVision and CooperSurgical. Our two business segments elevate standards of care with products and services in the fields of vision, fertility and women's health. For financial information relating to these business segments, refer to Note 12. Business Segment Information in Item 8. Financial Statements and Supplementary Data of this Annual Report. CooperVision is a global manufacturer providing products for contact lens wearers. CooperVision develops, manufactures and markets a broad range of single-use, two-week and monthly contact lenses, featuring advanced materials and optics. CooperVision designs its products to address vision challenges such as astigmatism, presbyopia and myopia with a broad collection of spherical, toric and multifocal contact lenses. CooperVision offers contact lenses in materials like silicone hydrogel Aquaform technology. CooperVision also manufactures and markets myopia management products, including the internally developed MiSight 1 day lens, as well as other specialty eyecare products such as orthokeratology (ortho-k) and scleral lenses. In November 2019, the MiSight 1 day lens became the first and only product approved by the United States Food and Drug Administration (FDA) for slowing the progression of myopia in children aged 8-12 at the initiation of treatment, and in August 2021, CooperVision received Chinese National Medical Products Administration (NMPA) approval for use of the MiSight 1 d